High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Antibodies, Monoclonal
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bone Marrow
/ drug effects
Dexamethasone
/ therapeutic use
Disease Progression
Drug Administration Schedule
Early Detection of Cancer
Humans
Lenalidomide
/ therapeutic use
Monoclonal Gammopathy of Undetermined Significance
/ diagnosis
Multiple Myeloma
/ diagnosis
Neoplasm, Residual
Oligopeptides
/ therapeutic use
Plasma Cells
/ drug effects
Randomized Controlled Trials as Topic
Smoldering Multiple Myeloma
/ diagnosis
Survival Analysis
Classification
Early myeloma
Smoldering myeloma
Treatment
Journal
Best practice & research. Clinical haematology
ISSN: 1532-1924
Titre abrégé: Best Pract Res Clin Haematol
Pays: Netherlands
ID NLM: 101120659
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
21
01
2020
accepted:
23
01
2020
entrez:
7
3
2020
pubmed:
7
3
2020
medline:
18
12
2020
Statut:
ppublish
Résumé
Multiple myeloma, a bone marrow cancer, is preceded by precursor stages called monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Over the past few years, highly effective and safe therapies have been made available to treat multiple myeloma. This represents a major breakthrough and has major therapeutic implications. Treatment for multiple myeloma has evolved to include treatment of precursor stages (early treatment) as these therapies are shown to be safe and effective also in smoldering myeloma. Randomized studies have shown that early treatment can delay the onset of multiple myeloma and even improve overall survival compared to observation in smoldering myeloma. The best therapeutic course and selection of patients with smoldering myeloma to treat is still a matter of debate. In this manuscript, we review the definition, management, clinical implications of smoldering myeloma and early detection of myeloma in the current context and with up-to-date data.
Identifiants
pubmed: 32139017
pii: S1521-6926(20)30013-X
doi: 10.1016/j.beha.2020.101152
pmc: PMC7069728
mid: NIHMS1556260
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Oligopeptides
0
daratumumab
4Z63YK6E0E
carfilzomib
72X6E3J5AR
Dexamethasone
7S5I7G3JQL
Lenalidomide
F0P408N6V4
isatuximab
R30772KCU0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101152Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest C. Kunacheewa reports no conflicts of interest. E. Manasanch has received research support from Sanofi, Quest Diagnostics, Novartis, JW. Pharma, Merck; consultant fees from Celgene, Janssen, Sanofi and Adaptive Biotechnologies.
Références
J Clin Oncol. 2013 Dec 1;31(34):4325-32
pubmed: 24145347
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Blood Adv. 2019 Aug 13;3(15):2400-2408
pubmed: 31405950
Blood. 2014 Jan 2;123(1):78-85
pubmed: 24144643
Blood. 2015 Nov 26;126(22):2475-8
pubmed: 26468228
Haematologica. 2015 Sep;100(9):1214-21
pubmed: 26022710
Br J Cancer. 2000 Apr;82(7):1254-60
pubmed: 10755397
Blood Cancer J. 2018 Jun 12;8(6):59
pubmed: 29895887
N Engl J Med. 2013 Aug 1;369(5):438-47
pubmed: 23902483
Leukemia. 2013 Jan;27(1):220-5
pubmed: 22902362
Leuk Res. 2018 Nov;74:130-136
pubmed: 30055822
Leukemia. 2018 Jun;32(6):1427-1434
pubmed: 29463830
Bone Marrow Transplant. 2016 Dec;51(12):1565-1568
pubmed: 27595280
N Engl J Med. 2007 Jun 21;356(25):2582-90
pubmed: 17582068
Leukemia. 2013 Apr;27(4):947-53
pubmed: 23183429
N Engl J Med. 2013 Oct 31;369(18):1764
pubmed: 24171529
N Engl J Med. 1980 Jun 12;302(24):1347-9
pubmed: 7374679
Leukemia. 2013 Mar;27(3):680-5
pubmed: 22902364
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Leukemia. 2014 Dec;28(12):2402-3
pubmed: 25079172
Blood Cancer J. 2018 Nov 8;8(11):107
pubmed: 30410066
Blood Adv. 2017 Sep 29;1(22):1911-1918
pubmed: 29296837
Leukemia. 2016 Feb;30(2):417-22
pubmed: 26490489
Leukemia. 2013 Aug;27(8):1738-44
pubmed: 23515097
Leukemia. 2013 Apr;27(4):941-6
pubmed: 23183428
Eur J Haematol. 2016 Sep;97(3):303-9
pubmed: 26710662
JAMA Oncol. 2017 Jan 01;3(1):28-35
pubmed: 27632282
Blood Adv. 2018 Jun 26;2(12):1470-1479
pubmed: 29945937
Br J Haematol. 2003 Jun;121(5):749-57
pubmed: 12780789
JAMA Oncol. 2015 Sep;1(6):746-54
pubmed: 26181891
Blood. 2008 Jan 15;111(2):785-9
pubmed: 17942755
J Clin Oncol. 2020 Apr 10;38(11):1126-1137
pubmed: 31652094
Blood Cancer J. 2016 Jul 29;6(7):e454
pubmed: 27471870
Leukemia. 2014 Sep;28(9):1902-8
pubmed: 24535407
J Clin Oncol. 2010 Mar 20;28(9):1606-10
pubmed: 20177023
Blood Cancer J. 2015 Oct 23;5:e364
pubmed: 26495861
Leukemia. 2017 Jan;31(1):130-135
pubmed: 27457702
N Engl J Med. 2018 Nov 8;379(19):1791-1795
pubmed: 30403935
Leukemia. 2018 Sep;32(9):2083-2085
pubmed: 29802327
Eur J Haematol. 1993 Feb;50(2):95-102
pubmed: 8440364
Clin Cancer Res. 2019 Jul 1;25(13):3772-3775
pubmed: 30890552
Br J Haematol. 2005 Sep;130(5):729-32
pubmed: 16115129
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Br J Haematol. 2003 Nov;123(4):631-6
pubmed: 14616966
Br J Haematol. 2018 Aug;182(4):495-503
pubmed: 29808907
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):194-204
pubmed: 29222256
Leuk Lymphoma. 2013 Oct;54(10):2215-8
pubmed: 23311294
Blood. 2014 Jan 2;123(1):4-5
pubmed: 24385493
Blood. 2007 Oct 1;110(7):2586-92
pubmed: 17576818
Leuk Lymphoma. 2022 Nov;63(11):2760-2761
pubmed: 35838493
Blood. 2015 May 14;125(20):3069-75
pubmed: 25838344